NexImmune, Inc. (NEXI)
| Market Cap | 293.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 22.61M |
| EPS (ttm) | -4.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,689 |
| Open | 12.98 |
| Previous Close | 12.88 |
| Day's Range | 12.19 - 13.20 |
| 52-Week Range | 10.10 - 28.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 8, 2021 |
About NEXI
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, ...
Financial Performance
Financial StatementsNews
NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates
GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes
GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
GAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune Strengthens Management Team with Key Appointments
GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference
GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune Announces Formation of Scientific Advisory Board
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...
NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Onco...
GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...
NexImmune Reports First Quarter 2021 Financial Results and Recent Updates
GAITHERSBURG, Md., May 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...
NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs
GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates
GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
5 Recent Red-Hot IPOs Are Being Added to the Russell 2000 Next Week
Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.
NexImmune to Present at the 2021 Barclays Global Healthcare Conference
GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.
NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase ...
GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own...
NexImmune Announces Pricing of Upsized Initial Public Offering Nasdaq:NEXI
NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy...
Immunotherapy biotech NexImmune files for an $86 million IPO
NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.
NexImmune IPO Registration Document (S-1)
NexImmune, Inc. has filed to go public with an IPO on the NASDAQ.